Stakeholders identify the value elements of comprehensive genomic profiling (CGP) they find most important, as well as options for innovative contracts.
Health outcomes, net costs, and reduction in uncertainty are the most important elements of comprehensive genomic profiling (CGP) for cancer treatment, and there is space for innovative contracts that address these elements, but it will be challenging, according to a poster presented at Virtual ISPOR 2021.
“Moving beyond traditional value frameworks and reimbursement models may be necessary to maximize the value and improve decision-making around reimbursement and use of CGP,” the researchers wrote.
They conducted qualitative interviews with 4 providers, 2 health insurers, and 2 employer representatives to identify the value elements of CGP important to stakeholders and understand the opportunities for innovative contracting.
All 4 providers, 1 insurer, and 1 employer representative identified “health outcomes: clinical decision support” as relevant to CGP, making it the top value element, followed by “net costs: general,” “reduction in uncertainty,” and “health outcomes: general.” The value elements considered less relevant for CGP were “value of hope,” “scientific spillovers,” and “equity.”
“CGP potentially plays a role in affecting other novel elements such as equity, scientific spillovers, the value of hope, and clinical trial enrollment; however, these elements were viewed unfavorably by stakeholders, mainly because these elements are considered hypothetical,” said author Woojung Lee, PharmD, PhD student, School of Pharmacy, University of Washington.
The respondents suggested some innovative contracts for CGP. These contracts were broken into 3 main types:
The biggest challenge of using innovative contracting for CGP was the administrative burden of tracking patients and assessing response criteria. Other key challenges highlighted were that use of CGP is not standardized, provider groups have their own CGP platform, difficulties choosing appropriate metrics, and that CFP is one piece of the treatment process.
“The administrative burden can be especially an issue for outcomes-guaranteed schemes, where patients often need to be followed up for a long time to observe their treatment outcome, Lee said.
Reference
Lee W, Grueger J, Spencer SJ, Veenstra DL, Carlson JJ. Value frameworks and innovative contracting for comprehensive genomic profiling. Presented at: Virtual ISPOR 2021; May 17-20, 2021. Poster PCN139.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More